Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 10/21 10:00:33 pm
40.5 USD   -0.59%
10/21 GLOBAL BLOOD TE : Abbott Laboratories, Ortho Clinical Diagnostics, B..
10/20 ABBOTT LABORATO : People's Republic of China Clears Abbott Acquisiti..
10/20 ABBOTT LABORATO : Jones Collombin Investment Counsel Inc Lowers stak..
News SummaryMost relevantAll newsSector news 

Former Abbott Drug Unit Recalls Synthroid Again

share with twitter share with LinkedIn share with facebook
share via e-mail
01/11/2013 | 09:36pm CEST

Abbott Laboratories' (>> Abbott Laboratories) former pharmaceutical unit, now spun off as AbbVie Inc. (>> AbbVie Inc), recently recalled more than 28,520 bottles of the thyroid-hormone replacement therapy Synthroid over a dose mix-up, marking the second recall of the drug in six months.

One lot of 150-microgram Synthroid tablets was recalled because one bottle was found to contain lower-dose, 75-microgram tablets, AbbVie spokesman Gregory Miley said Friday. The voluntary recall was initiated in early December as a precaution, he said.

The cause was a "manufacturing line clearance error," he said, and AbbVie has taken corrective action. The company isn't aware of any increase in patient complaints or adverse events associated with the label error.

AbbVie was spun off to Abbott shareholders as an independent company at the start of January. AbbVie assumed Synthroid's U.S. marketing rights, though Abbott Labs continues to market the drug outside the U.S.

In July, Abbott recalled three lots of Synthroid because some bottles had defects that could affect the stability of the tablets at the end of shelf life. More than 136,500 bottles of Synthroid were subject to that recall, though Abbott said a majority of them remained under Abbott's control and weren't shipped out.

Both Synthroid recalls were classified by the FDA as Class II, which is typically applied in situations where a product might cause a temporary health problem or pose only a slight threat of a serious health problem.

Synthroid is a synthetic thyroid hormone used by people with hypothyroidism, in which the thyroid gland doesn't produce enough natural thyroid hormone.

Abbott reported $461 million of global Synthroid sales for the first nine months of 2012.

AbbVie shares were recently down a penny at $33.61.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Abbott Laboratories, AbbVie Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
10/21 GLOBAL BLOOD TESTING MARKET 2016 : Abbott Laboratories, Ortho Clinical Diagnosti..
10/21 DGAP-NEWS : Abbott Laboratories: Statement re Delisting From Exchange
10/20 ABBOTT LABORATORIES : An Application for the Trademark "SIMILAC NEWBORN" Has Bee..
10/20 ABBOTT LABORATORIES : An Application for the Trademark "HI-TORQUE VERSACORE" Has..
10/20 ABBOTT LABORATORIES : An Application for the Trademark "TRUSTED BY PLAYERS. PROV..
10/20 ABBOTT LABORATORIES : People's Republic of China Clears Abbott Acquisition of Al..
10/20 ABBOTT LABORATORIES : Jones Collombin Investment Counsel Inc Lowers stake in Abb..
10/20 ABBOTT LABORATORIES : Gemmer Asset Management buys $153,941 stake in Abbott Labo..
10/20 Terumo to buy U.S. vascular closure device businesses for $1.1 billion
More news
Sector news : Pharmaceuticals - NEC
09:22a GSK files potential $1 billion shingles vaccine for U.S. approval
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJPFIZER : J&J Brushes Off Pfizer's Challenge -- WSJ
10/18 JOHNSON & JOHNSON : J&J shares lose ground on fears of Pfizer's answer to Remica..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/21 60% Return From Reynolds' Smoking Hot Opportunity
10/21 Alere shareholders back Abbott deal
10/20 SetPoint Leads The Crohn's Medtech Race By Being The Only Entrant
10/20 Don't Worry, It's About To Get Worse
10/19 Secret M&A Target List Leaked
Financials ($)
Sales 2016 20 941 M
EBIT 2016 3 963 M
Net income 2016 1 566 M
Debt 2016 3 122 M
Yield 2016 2,56%
P/E ratio 2016 25,49
P/E ratio 2017 17,98
EV / Sales 2016 2,99x
EV / Sales 2017 2,87x
Capitalization 59 535 M
More Financials
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 47,5 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.71%198 298
PFIZER INC.-0.31%195 193
MERCK & CO., INC.15.87%169 231
More Results